ATE555799T1 - Von blutzellen abstammende mikropartikel als blutstillende mittel zur kontrolle von blutungen und behandlung von blutungsstörungen - Google Patents

Von blutzellen abstammende mikropartikel als blutstillende mittel zur kontrolle von blutungen und behandlung von blutungsstörungen

Info

Publication number
ATE555799T1
ATE555799T1 AT05849361T AT05849361T ATE555799T1 AT E555799 T1 ATE555799 T1 AT E555799T1 AT 05849361 T AT05849361 T AT 05849361T AT 05849361 T AT05849361 T AT 05849361T AT E555799 T1 ATE555799 T1 AT E555799T1
Authority
AT
Austria
Prior art keywords
microparticles
bleeding
blood cell
cell derived
derived microparticles
Prior art date
Application number
AT05849361T
Other languages
English (en)
Inventor
Wenche Jy
Joaquin Jimenez
Lawrence Horstmann
Yeon Ahn
Eugene Ahn
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Application granted granted Critical
Publication of ATE555799T1 publication Critical patent/ATE555799T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05849361T 2004-12-07 2005-12-07 Von blutzellen abstammende mikropartikel als blutstillende mittel zur kontrolle von blutungen und behandlung von blutungsstörungen ATE555799T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63341704P 2004-12-07 2004-12-07
PCT/US2005/044064 WO2006062945A2 (en) 2004-12-07 2005-12-07 Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders

Publications (1)

Publication Number Publication Date
ATE555799T1 true ATE555799T1 (de) 2012-05-15

Family

ID=36578476

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05849361T ATE555799T1 (de) 2004-12-07 2005-12-07 Von blutzellen abstammende mikropartikel als blutstillende mittel zur kontrolle von blutungen und behandlung von blutungsstörungen

Country Status (9)

Country Link
US (1) US8105632B2 (de)
EP (1) EP1819230B1 (de)
JP (1) JP5204490B2 (de)
AT (1) ATE555799T1 (de)
DK (1) DK1819230T3 (de)
ES (1) ES2390317T3 (de)
PL (1) PL1819230T3 (de)
PT (1) PT1819230E (de)
WO (1) WO2006062945A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155764B1 (en) * 2004-12-07 2015-10-13 University Of Miami Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding
ES2577514T3 (es) 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
DK2510946T3 (en) 2007-02-07 2015-11-02 Univ California Conjugates of synthetic fluorescent agonists and their applications
FR2917172B1 (fr) * 2007-06-07 2014-01-03 Inst Nat Sante Rech Med Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation
US20090062233A1 (en) * 2007-08-09 2009-03-05 Xin Ji Modified starch material of biocompatible hemostasis
EP2449384B1 (de) * 2009-07-01 2016-04-20 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren zur vorhersage des kardiovaskulären sterberisikos
EP2625264B1 (de) 2010-10-08 2022-12-07 Terumo BCT, Inc. Verfahren und systeme für züchtung und ernte von zellen in einem hohlfaser-bioreaktorsystem mit steuerungsbedingungen
US20130316011A1 (en) * 2011-01-28 2013-11-28 University Of Miami Expanded Utility of Red Cell-Derived Microparticles (RMP) for Treatment of Bleeding
JP2012168012A (ja) * 2011-02-14 2012-09-06 Nippon Koden Corp 血管内皮障害を検査するための新規な検査方法および検査用キット
WO2012135032A2 (en) * 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US10004764B2 (en) * 2013-11-07 2018-06-26 University of Pittsburgh—of the Commonwealth System of Higher Education Red blood cell membrane-derived microparticles and their use for the treatment of lung disease
EP3068866B1 (de) 2013-11-16 2018-04-25 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
US10538738B2 (en) * 2014-05-19 2020-01-21 Eleftherios Papoutsakis Megakaryocytic particles and microparticles for cell therapy and fate modification of stem and progenitor cells
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
EP3265116B1 (de) * 2015-03-04 2021-06-02 University of Rochester Systemische und topische anwendung von thrombozytenmikropartikel zur behandlung von blutungen bei traumapatienten
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10543286B2 (en) 2015-10-07 2020-01-28 The Research Foundation For The State University Of New York Methods for increasing platelet count by inhibiting biliverdin IXβ reductase
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
JP6896516B2 (ja) * 2016-07-25 2021-06-30 シスメックス株式会社 血液分析装置および血液分析方法
WO2018102409A2 (en) 2016-11-30 2018-06-07 University Of Miami Rmp composition and methods of use
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
CN115768877A (zh) 2020-05-11 2023-03-07 斯特姆生物公司 与巨核细胞来源的细胞外囊泡相关的组合物和方法
US12043823B2 (en) 2021-03-23 2024-07-23 Terumo Bct, Inc. Cell capture and expansion
EP4329783A4 (de) 2021-04-26 2025-04-02 STRM.Bio Incorporated Zusammensetzungen und verfahren im zusammenhang mit extrazellulären vesikeln aus megakaryozyten für fanconi-anämie
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
JP2025536478A (ja) * 2022-11-18 2025-11-06 ジョンシャン ユニバーシティ 体外血液凝固促進薬又は体外止血薬の調製における小胞の使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2227752C2 (ru) 1998-11-12 2004-04-27 Новолитикс Инк. Способы перекрытия кровотока и композиции для их реализации

Also Published As

Publication number Publication date
EP1819230A2 (de) 2007-08-22
PL1819230T3 (pl) 2013-02-28
EP1819230B1 (de) 2012-05-02
WO2006062945A3 (en) 2006-12-07
JP5204490B2 (ja) 2013-06-05
WO2006062945A2 (en) 2006-06-15
US8105632B2 (en) 2012-01-31
ES2390317T3 (es) 2012-11-08
DK1819230T3 (da) 2012-08-20
EP1819230A4 (de) 2009-08-12
JP2008522974A (ja) 2008-07-03
PT1819230E (pt) 2012-08-07
US20080069807A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
ATE555799T1 (de) Von blutzellen abstammende mikropartikel als blutstillende mittel zur kontrolle von blutungen und behandlung von blutungsstörungen
SA521422031B1 (ar) مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
DE602005020611D1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
EA201691235A1 (ru) Модифицированные серпины для лечения нарушений свертываемости крови
ATE460402T1 (de) Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1- rezeptors
BRPI0718688A8 (pt) Composições de baixa irritação e métodos para preparar as mesmas
ATE553093T1 (de) Indazolderivate zur hemmung von trpv1 und verwendungen davon
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
EA200601766A1 (ru) Производные имидазола
EA201100424A1 (ru) Новые ингибиторы
EA201391030A1 (ru) Композиции моноциклина для местного применения и способы их применения
ATE481134T1 (de) Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
EA202090513A1 (ru) Агенты, модулирующие функции бета-катенина, и связанные способы
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
PH12012502070A1 (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
EA201501123A8 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
EP2910247A4 (de) Zusammensetzungen zur vermeidung oder behandlung von hautallergien mit gpcr19-stoffen als wirkstoffe